Combo Oral Suspension for Pain Discontinued

The Food and Drug Administration posted the discontinuation notice for Capital and Codeine Oral Suspension.
The Food and Drug Administration posted the discontinuation notice for Capital and Codeine Oral Suspension.

The Food and Drug Administration (FDA) has posted a discontinuation notice for Capital and Codeine (acetaminophen, codeine phosphate; Valeant) Oral Suspension. 

Capital and Codeine Oral Suspension combines codeine, a centrally-acting analgesic, with acetaminophen, a peripherally-acting analgesic. It is indicated for the relief of mild to moderate pain

Related Articles

Capital and Codeine, a CV controlled substance, was supplied as a 120mg/12mg per 5mL fruit punch-flavored suspension in 16oz bottles (NDC 0187-0003-01). The Company stated that the product discontinuation was a result of a business decision.

For more information call (800) 321-4576 or visit Valeant.com.